Imugene Limited (ASX:IMU) was up 26.9% on Monday . The stock traded as high as A$0.04 ($0.03) and last traded at A$0.03 ($0.02), approximately 199,192,827 shares traded hands during trading. The stock had previously closed at A$0.03 ($0.02).
The company has a current ratio of 9.67, a quick ratio of 9.60 and a debt-to-equity ratio of 0.45. The firm has a market cap of $83.03 million and a price-to-earnings ratio of -16.50. The firm has a 50-day moving average of A$0.02 and a two-hundred day moving average of A$0.02.
About Imugene (ASX:IMU)
Imugene Limited, an immuno-oncology biopharmaceutical company, develops mimotopes and small molecule drug candidates in Australia. Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptors, which are expressed on the surface of tumors, including gastric, breast, ovarian, and pancreatic cancers.
Featured Story: Futures Contract
Receive News & Ratings for Imugene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imugene and related companies with MarketBeat.com's FREE daily email newsletter.